Delta样配体3/CD3 IgG样T细胞衔接器Obrixtamig(BI 764532)在DLL3阳性小细胞肺癌或神经内分泌癌患者中的I期剂量递增结果
这项I期研究评估了Obrixtamig(BI 764532)在经治DLL3阳性小细胞肺癌、肺外神经内分泌癌或肺大细胞神经内分泌癌患者中的剂量递增。截至2024年2月21日,168例患者接受治疗,未达到最大耐受剂量。总体客观缓解率为23%(95%CI 17.4%至30.2%),中位缓解持续时间为8.5个月(95%CI 6.2至未达到),6个月缓解持续率70%(95%CI 53%至88%)。
要点
- 最常见治疗相关不良事件为细胞因子释放综合征(任何级别57%,≥3级3%),多发生于早期且可逆。
- 方案B2/B3所有患者均接受最低有效剂量(≥90 μg/kg每周一次或每3周一次),客观缓解率28%(95%CI 20.7%至35.9%)。
- 方案B2/B3在小细胞肺癌、肺外神经内分泌癌和肺大细胞神经内分泌癌的客观缓解率分别为21%(95%CI 12.9%至33.1%)、27%(95%CI 17.4%至39.6%)和70%(95%CI 39.7%至89.2%)。
核心结论
- Obrixtamig以递增剂量后目标剂量90-1080 μg/kg(每周一次或每3周一次)给药,在经重度治疗的DLL3阳性肿瘤患者中显示出可耐受性和疗效,支持在小细胞肺癌、肺外神经内分泌癌和肺大细胞神经内分泌癌中进一步探索。
研究设计与样本
- I期剂量递增研究,纳入经治DLL3阳性小细胞肺癌、肺外神经内分泌癌或肺大细胞神经内分泌癌患者,接受四种静脉给药方案(A:固定剂量每3周一次;B1:固定剂量每周一次;B2:递增剂量每周一次两周后目标剂量每周一次;B3:递增剂量每周一次3周、目标剂量每周一次3周后每3周一次),主要目标为最大耐受剂量。
主要发现
- 截至2024年2月21日,168例患者接受Obrixtamig治疗,72%接受过≥2线既往抗癌治疗,51%接受过既往抗PD-1/PD-L1治疗。
- 最大耐受剂量评估期间发生7例剂量限制性毒性(方案A n=1;方案B2 n=6),未达到最大耐受剂量。
- 最常见治疗相关不良事件为细胞因子释放综合征(任何级别57%;≥3级3%),多数发生在早期且可逆。
- 所有剂量、方案和肿瘤类型的总体客观缓解率为23%(95%CI 17.4%至30.2%),中位缓解持续时间8.5个月(95%CI 6.2至未达到),6个月缓解持续率70%(95%CI 53%至88%)。
- 方案B2/B3所有患者接受最低有效剂量(≥90 μg/kg每周一次或每3周一次),客观缓解率28%(95%CI 20.7%至35.9%);方案B2/B3在小细胞肺癌、肺外神经内分泌癌和肺大细胞神经内分泌癌的客观缓解率分别为21%(95%CI 12.9%至33.1%)、27%(95%CI 17.4%至39.6%)和70%(95%CI 39.7%至89.2%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinomas (epNECs), or large cell neuroendocrine carcinoma of the lung (LCNEC-L). METHODS: Patients received escalating intravenous obrixtamig doses using four regimens: a fixed dose once every 3 weeks (A); a fixed dose once weekly (B1); a step-up dose once weekly for two weeks and target dose once weekly (B2); and a step-up dose once weekly for 3 weeks, target dose once weekly for 3 weeks, and once every 3 weeks thereafter (B3). The primary objective was maximum tolerated dose (MTD). Secondary objectives included safety, pharmacokinetics, and tumor response (RECIST v1.1). RESULTS: As of February 21, 2024, 168 patients received obrixtamig, 72% received ≥2 lines of previous anticancer therapy, and 51% received previous anti-PD-1/PD-L1 therapy. Seven dose-limiting toxicities occurred during MTD evaluation (Regimen A, n = 1; Regimen B2, n = 6). MTD was not reached. The most common treatment-related adverse event was cytokine release syndrome (any grade: 57%; grade ≥3: 3%); most cases occurred early and were reversible. Across all doses, regimens, and tumor types, the overall response rate (ORR) was 23% (95% CI, 17.4% to 30.2%), the median duration of response (DoR) was 8.5 months (95% CI, 6.2 to not reached), and the 6-month DoR rate was 70% (95% CI, 53% to 88%). All patients in Regimens B2/B3 received the minimum effective dose (≥90 μg/kg once weekly or once every 3 weeks), achieving an ORR of 28% (95% CI, 20.7% to 35.9%). With Regimens B2/B3, ORRs were 21% (95% CI, 12.9% to 33.1%), 27% (95% CI, 17.4% to 39.6%), and 70% (95% CI, 39.7% to 89.2%) for SCLC, epNECs, and LCNEC-L, respectively. CONCLUSION: The demonstrated tolerability and efficacy of obrixtamig regimens, administered as step-up followed by target doses of 90-1,080 μg/kg (once weekly or once every 3 weeks), in patients with heavily pretreated DLL3-positive tumors support further exploration in SCLC, epNEC, and LCNEC-L.
引用
- Wermke M, Gambardella V, Kuboki Y, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol. 2025. PMID: 40706016. doi:10.1200/JCO-25-00363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。